

Pentasa[®] (mesalamine) – First-time generic

- On May 17, 2022, [Sun Pharma launched](#) an [AB-rated](#) generic version of Takeda's [Pentasa \(mesalamine\)](#) 500 mg extended-release capsules.
 - Sun Pharma was granted 180-days of Competitive Generic Therapy exclusivity for generic Pentasa.
 - In addition, Prasco will launch an authorized brand alternative of Pentasa shortly.
- Pentasa is approved for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis.
- Mesalamine is also available as a brand 250 mg extended-release capsule (Pentasa), generic [delayed-release capsule](#), generic [extended-release 0.375 gram capsule](#), generic [enema](#), generic rectal [suppository](#), and generic [delayed-release tablet](#).
 - Mesalamine delayed-release capsule is approved for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older and for the maintenance of remission of ulcerative colitis in adults.
 - Mesalamine extended-release 0.375 gram capsules is approved for the maintenance of remission of ulcerative colitis in adults.
 - Mesalamine enema is approved for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults.
 - Mesalamine rectal suppository is approved in adults for the treatment of mildly to moderately active ulcerative proctitis.
 - Mesalamine delayed-release tablet is approved for the induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.
- According to IQVIA Health data, Pentasa 500 mg had annualized U.S. sales of approximately \$213 million for the 12 months ending March 2022.